SLAMF7 and Miyoshi myopathy: Elotuzumab is a humanized IgG kappa monoclonal antibody that targets the signaling lymphocyte activation molecule family member 7 (SLAMF7) to promote MM killing, predominantly through NK cell-mediated ADCC, as well as macrophage-mediated ADCP [195,196,197,198].